HomeORMP • NASDAQ
Oramed Pharmaceuticals, Inc.
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.09M | 6.77% |
Net income | -19.62M | -508.91% |
Net profit margin | — | — |
Earnings per share | -0.48 | -500.00% |
EBITDA | -3.04M | -6.97% |
Effective tax rate | -6.12% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 142.30M | -18.70% |
Total assets | 165.08M | -28.50% |
Total liabilities | 9.56M | -88.44% |
Total equity | 155.52M | — |
Shares outstanding | 40.31M | — |
Price to book | 0.55 | — |
Return on assets | -4.42% | — |
Return on capital | -4.64% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -19.62M | -508.91% |
Cash from operations | -7.10M | -923.20% |
Cash from investing | -34.26M | 54.39% |
Cash from financing | -1.29M | -101.73% |
Net change in cash | -42.65M | -3,183.22% |
Free cash flow | -277.63K | 40.85% |
Previous close
$2.13
Day range
$2.11 - $2.20
Year range
$1.96 - $3.09
Market cap
89.74M USD
Avg Volume
141.98K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange. Wikipedia
CEO
Founded
2006
Website
Employees
13
